A detailed history of Macquarie Group LTD transactions in Catalent, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 706,769 shares of CTLT stock, worth $44.9 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
706,769
Previous 5,665 12376.06%
Holding current value
$44.9 Million
Previous $318,000 13361.64%
% of portfolio
0.05%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.16 - $60.96 $39.4 Million - $42.7 Million
701,104 Added 12376.06%
706,769 $42.8 Million
Q2 2024

Aug 09, 2024

SELL
$53.58 - $57.02 $7.66 Million - $8.16 Million
-143,029 Reduced 96.19%
5,665 $318,000
Q1 2024

May 14, 2024

SELL
$42.56 - $59.82 $2.49 Million - $3.49 Million
-58,415 Reduced 28.2%
148,694 $8.39 Million
Q4 2023

Feb 14, 2024

BUY
$32.18 - $46.57 $253,481 - $366,831
7,877 Added 3.95%
207,109 $9.31 Million
Q3 2023

Nov 14, 2023

BUY
$44.2 - $50.2 $96,223 - $109,285
2,177 Added 1.1%
199,232 $9.07 Million
Q2 2023

Aug 14, 2023

BUY
$31.86 - $67.26 $364,637 - $769,790
11,445 Added 6.17%
197,055 $8.54 Million
Q1 2023

May 15, 2023

SELL
$45.44 - $74.26 $1.59 Million - $2.6 Million
-34,995 Reduced 15.86%
185,610 $12.2 Million
Q4 2022

Feb 21, 2023

SELL
$41.39 - $81.0 $506,034 - $990,306
-12,226 Reduced 5.25%
220,605 $9.93 Million
Q3 2022

Nov 14, 2022

SELL
$72.36 - $113.1 $5.32 Million - $8.31 Million
-73,505 Reduced 23.99%
232,831 $16.8 Million
Q2 2022

Aug 15, 2022

SELL
$87.2 - $114.05 $3.91 Million - $5.12 Million
-44,886 Reduced 12.78%
306,336 $32.9 Million
Q1 2022

May 16, 2022

BUY
$94.19 - $124.49 $6.75 Million - $8.92 Million
71,687 Added 25.65%
351,222 $39 Million
Q4 2021

Feb 11, 2022

BUY
$119.57 - $139.07 $3.68 Million - $4.28 Million
30,747 Added 12.36%
279,535 $35.8 Million
Q3 2021

Nov 12, 2021

BUY
$109.17 - $142.35 $12 Million - $15.7 Million
110,116 Added 79.41%
248,788 $33.1 Million
Q2 2021

Aug 13, 2021

BUY
$100.34 - $115.69 $899,247 - $1.04 Million
8,962 Added 6.91%
138,672 $15 Million
Q1 2021

May 14, 2021

BUY
$101.51 - $125.27 $2.92 Million - $3.61 Million
28,802 Added 28.54%
129,710 $13.7 Million
Q4 2020

Feb 16, 2021

SELL
$85.88 - $105.36 $40.5 Million - $49.7 Million
-472,010 Reduced 82.39%
100,908 $10.5 Million
Q3 2020

Nov 13, 2020

SELL
$72.74 - $92.5 $478,774 - $608,835
-6,582 Reduced 1.14%
572,918 $49.1 Million
Q2 2020

Aug 11, 2020

SELL
$48.02 - $79.04 $18.2 Million - $30 Million
-379,840 Reduced 39.59%
579,500 $42.5 Million
Q1 2020

May 15, 2020

SELL
$36.95 - $62.95 $4.78 Million - $8.14 Million
-129,297 Reduced 11.88%
959,340 $49.8 Million
Q4 2019

Feb 14, 2020

BUY
$47.06 - $56.64 $5.1 Million - $6.14 Million
108,370 Added 11.06%
1,088,637 $61.3 Million
Q3 2019

Nov 14, 2019

SELL
$47.45 - $58.05 $11.5 Million - $14 Million
-241,327 Reduced 19.76%
980,267 $46.7 Million
Q2 2019

Aug 14, 2019

SELL
$39.26 - $54.21 $4.13 Million - $5.7 Million
-105,119 Reduced 7.92%
1,221,594 $66.2 Million
Q1 2019

May 15, 2019

SELL
$29.84 - $43.92 $13.3 Million - $19.6 Million
-447,159 Reduced 25.21%
1,326,713 $53.9 Million
Q4 2018

Feb 15, 2019

SELL
$29.95 - $46.34 $20.3 Million - $31.4 Million
-676,553 Reduced 27.61%
1,773,872 $55.3 Million
Q3 2018

Nov 15, 2018

BUY
$40.12 - $45.55 $4.07 Million - $4.62 Million
101,366 Added 4.32%
2,450,425 $112 Million
Q2 2018

Aug 14, 2018

BUY
$38.72 - $42.52 $18.3 Million - $20.1 Million
472,228 Added 25.16%
2,349,059 $98.4 Million
Q1 2018

May 11, 2018

BUY
$39.4 - $47.39 $4.82 Million - $5.79 Million
122,253 Added 6.97%
1,876,831 $77.1 Million
Q4 2017

Feb 15, 2018

SELL
$37.27 - $43.02 $11.7 Million - $13.5 Million
-314,745 Reduced 15.21%
1,754,578 $72.1 Million
Q3 2017

Nov 08, 2017

BUY
$33.75 - $41.67 $69.8 Million - $86.2 Million
2,069,323
2,069,323 $82.6 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.